Xenon Pharmaceuticals Inc (XENE)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Ian C. Mortimer
Employees:
150
200 - 3650 GILMORE WAY, BURNABY, CANADA V5G 48W
(604) 484-3300

Xenon Pharmaceuticals Inc. engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy. XEN007, a central nervous system-acting calcium channel modulator, is in Phase II clinical trials.

Data derived from most recent annual or quarterly report
Market Cap 2.238 Billion Shares Outstanding62.544 Million Avg 30-day Volume 403.672 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.57
Price to Revenue253.0397 Debt to Equity0.0 EBITDA-132.344 Million
Price to Book Value3.3086 Operating Margin-1368.9103 Enterprise Value1.666 Billion
Current Ratio26.443 EPS Growth-0.164 Quick Ratio26.124
1 Yr BETA 0.8826 52-week High/Low 41.39 / 24.94 Profit Margin-1328.9485
Operating Cash Flow Growth-41.6218 Altman Z-Score43.319 Free Cash Flow to Firm -92.869 Million
Earnings Report2023-05-09
View SEC Filings from XENE instead.

View recent insider trading info

Xenon Pharmaceuticals Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding XENE (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding XENE

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2023-03-24 by KENNEY CHRISTOPHER JOHN
  • 4: filed on 2023-03-14 by VON SEGGERN CHRISTOPHER
  • 4: filed on 2023-03-14 by ROBIN SHERRINGTON
  • 4: filed on 2023-03-14 by DIFABIO ANDREA
  • 4: filed on 2023-03-14 by MORTIMER IAN
  • 4: filed on 2023-03-14 by KENNEY CHRISTOPHER JOHN
  • 4: filed on 2023-03-14 by EMPFIELD JAMES R.
  • 4: filed on 2023-03-14 by AULIN SHERRY
  • 4: filed on 2023-03-09 by PIMSTONE SIMON N.
  • 4: filed on 2022-11-09 by DIFABIO ANDREA

    • Events (8k)

  • 8-K: filed on 2023-03-14:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-03-08:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-03-01:
    Item 2.02: Results of Operations and Financial Condition
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-11-08:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-11-07:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-08-09:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-06-23:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-06-21:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-06-02:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.07: Submission of Matters to a Vote of Security Holders
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-05-10:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    19.9 Thousand total shares from 3 transactions

    Exercise Derivative Conversion (M)

    72 Thousand total shares from 2 transactions

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    KENNEY CHRISTOPHER JOHN CHIEF MEDICAL OFFICER

    • Officer
    		 0 2023-03-24 2

    MORTIMER IAN PRESIDENT & CEO

    • Officer
    • Director
    		 0 2023-03-10 1

    ROBIN SHERRINGTON EVP, STRATEGY & INNOVATION

    • Officer
    		 0 2023-03-10 2

    EMPFIELD JAMES R. EVP, DRUG DISCOVERY

    • Officer
    		 0 2023-03-10 2

    DIFABIO ANDREA CHIEF LEGAL OFFICER

    • Officer
    		 0 2023-03-10 3

    VON SEGGERN CHRISTOPHER CHIEF COMMERCIAL OFFICER

    • Officer
    		 0 2023-03-10 1

    AULIN SHERRY CHIEF FINANCIAL OFFICER

    • Officer
    		 0 2023-03-10 2

    PIMSTONE SIMON N.

    • Director
    		 55,006 2023-03-07 3

    AZAB MOHAMMAD

    • Director
    		 69,905 2022-12-12 2

    PATOU GARY

    • Director
    		 59,646 2022-11-23 2

    MACHADO PATRICK

    • Director
    		 18,000 2022-06-28 1

    SVORONOS DAWN

    • Director
    		 18,000 2022-06-28 1

    GANNON STEVEN

    • Director
    		 18,000 2022-06-28 1

    GAROFALO ELIZABETH A.

    • Director
    		 18,000 2022-06-28 1

    HAYDEN MICHAEL R

    • Director
    		 10,000 2021-06-03 0

    HOLLER FRANK A

    • Director
    		 144,837 2021-05-27 0

    TARNOW MICHAEL M

    • Director
    		 77,942 2021-05-18 0

    DESJARDINS CLARISSA

    • Director
    		 0 2020-06-01 0

    AYCARDI-FONSECA ERNESTO CMO

    • Officer
    		 0 2020-03-12 0

    SCHELLER RICHARD H

    • Director
    		 0 2019-09-16 0

    COHEN CHARLES J. VP, BIOLOGY

    • Officer
    		 6,550 2018-12-11 0

    BVF PARTNERS L P/IL

    BIOTECHNOLOGY VALUE FUND L P

    BIOTECHNOLOGY VALUE FUND II LP

    BIOTECHNOLOGY VALUE TRADING FUND OS LP

    BVF PARTNERS OS LTD.

    BVF INC/IL

    LAMPERT MARK N

    • 10% Owner
    • SEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSES
    		No longer subject to file 2018-03-27 0

    GOLDBERG Y. PAUL SVP, CLINICAL DEVELOPMENT

    • Officer
    		 0 2017-10-23 0

    WINQUIST RAYMOND HEAD, TRANSLATIONAL RESEARCH

    • Officer
    		 1,000 2017-08-18 0

    EVANS JOHNSTON L

    • Director
    		 0 2015-05-04 0

    STEIN EVAN A.

    • Director
    		 No longer subject to file 2015-04-30 0

    CORRAINI KAREN G. GEN. COUNSEL & CORP. SECRETARY

    • Officer
    		 0 2015-03-17 0

    MX ASSOCIATES, LLP

    • 10% Owner
    		 No longer subject to file 2014-12-31 0

    BRIDGER GARY EVP, RESEARCH & DEVELOPMENT

    • Officer
    		 0 2014-11-21 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    KENNEY CHRISTOPHER JOHN - Officer CHIEF MEDICAL OFFICER

    		2023-03-24 19:18:57 -0400 2023-03-24 S 700 $35.01 d 0 direct 0.5226 0.5226 2 0.0 1

    EMPFIELD JAMES R. - Officer EVP, DRUG DISCOVERY

    		2023-03-14 16:27:38 -0400 2023-03-10 A 75,000 a 75,000 direct

    AULIN SHERRY - Officer CHIEF FINANCIAL OFFICER

    		2023-03-14 16:25:54 -0400 2023-03-10 A 120,000 a 120,000 direct

    MORTIMER IAN - Director - Officer PRESIDENT & CEO

    		2023-03-14 16:36:15 -0400 2023-03-10 A 380,000 a 380,000 direct

    KENNEY CHRISTOPHER JOHN - Officer CHIEF MEDICAL OFFICER

    		2023-03-14 16:32:22 -0400 2023-03-10 A 120,000 a 120,000 direct

    ROBIN SHERRINGTON - Officer EVP, STRATEGY & INNOVATION

    		2023-03-14 16:46:02 -0400 2023-03-10 A 75,000 a 75,000 direct

    DIFABIO ANDREA - Officer CHIEF LEGAL OFFICER

    		2023-03-14 16:44:33 -0400 2023-03-10 A 45,000 a 45,000 direct

    VON SEGGERN CHRISTOPHER - Officer CHIEF COMMERCIAL OFFICER

    		2023-03-14 16:47:44 -0400 2023-03-10 A 90,000 a 90,000 direct

    PIMSTONE SIMON N. - Director

    		2023-03-09 18:21:59 -0500 2023-03-07 F 1,618 $37.13 d 63,248 direct 0.1463 -1.7262 0.907 3 -1.7262 6

    PIMSTONE SIMON N. - Director

    		2023-03-09 18:21:59 -0500 2023-03-07 F 2,160 $37.13 d 44,992 direct 0.1463 -1.7262 0.907 3 -1.7262 6

    PIMSTONE SIMON N. - Director

    		2023-03-09 18:21:59 -0500 2023-03-07 S 8,242 $36.94 d 55,006 direct 0.1463 -1.7262 0.907 3 -1.7262 6

    PIMSTONE SIMON N. - Director

    		2023-03-09 18:21:59 -0500 2023-03-07 S 10,990 $37.01 d 34,002 direct 0.1463 -1.7262 0.907 3 -1.7262 6

    PIMSTONE SIMON N. - Director

    		2023-03-09 18:21:59 -0500 2023-03-07 M 30,864 $2.59 a 64,866 direct 0.1463 -1.7262 0.907 3 -1.7262 6

    PIMSTONE SIMON N. - Director

    		2023-03-09 18:21:59 -0500 2023-03-07 M 30,864 d 0 direct

    PIMSTONE SIMON N. - Director

    		2023-03-09 18:21:59 -0500 2023-03-07 M 41,152 $2.68 a 47,152 direct 0.1463 -1.7262 0.907 3 -1.7262 6

    PIMSTONE SIMON N. - Director

    		2023-03-09 18:21:59 -0500 2023-03-07 M 41,152 d 0 direct

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    XENON PHARMACEUTICALS INC XENE 2023-03-31 22:15:04 UTC 4.4119 0.4081 450000
    XENON PHARMACEUTICALS INC XENE 2023-03-31 21:45:05 UTC 4.4119 0.4081 450000
    XENON PHARMACEUTICALS INC XENE 2023-03-31 21:15:03 UTC 4.4119 0.4081 450000
    XENON PHARMACEUTICALS INC XENE 2023-03-31 20:45:04 UTC 4.4119 0.4081 450000
    XENON PHARMACEUTICALS INC XENE 2023-03-31 20:15:04 UTC 4.4119 0.4081 450000
    XENON PHARMACEUTICALS INC XENE 2023-03-31 19:45:04 UTC 4.4119 0.4081 450000
    XENON PHARMACEUTICALS INC XENE 2023-03-31 19:15:04 UTC 4.4119 0.4081 450000
    XENON PHARMACEUTICALS INC XENE 2023-03-31 18:45:04 UTC 4.4119 0.4081 450000
    XENON PHARMACEUTICALS INC XENE 2023-03-31 18:15:04 UTC 4.4119 0.4081 450000
    XENON PHARMACEUTICALS INC XENE 2023-03-31 17:45:04 UTC 4.4119 0.4081 450000
    XENON PHARMACEUTICALS INC XENE 2023-03-31 17:15:03 UTC 4.4119 0.4081 450000
    XENON PHARMACEUTICALS INC XENE 2023-03-31 16:45:04 UTC 4.4119 0.4081 450000
    XENON PHARMACEUTICALS INC XENE 2023-03-31 16:15:04 UTC 4.4119 0.4081 450000
    XENON PHARMACEUTICALS INC XENE 2023-03-31 15:45:04 UTC 4.4119 0.4081 450000
    XENON PHARMACEUTICALS INC XENE 2023-03-31 15:15:03 UTC 4.4119 0.4081 450000
    XENON PHARMACEUTICALS INC XENE 2023-03-31 14:45:04 UTC 4.4119 0.4081 450000
    XENON PHARMACEUTICALS INC XENE 2023-03-31 14:15:04 UTC 4.4119 0.4081 450000
    XENON PHARMACEUTICALS INC XENE 2023-03-31 13:45:03 UTC 4.4119 0.4081 450000
    XENON PHARMACEUTICALS INC XENE 2023-03-31 13:15:03 UTC 4.4119 0.4081 450000
    XENON PHARMACEUTICALS INC XENE 2023-03-31 12:45:03 UTC 4.4119 0.4081 450000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    FundVantage Trust- Gotham Enhanced Index Plus Fund XENE -5.0 shares, $-56.7 2020-03-31 N-PORT
    FundVantage Trust- Gotham Index Plus All-Cap Fund XENE -4.0 shares, $-45.36 2020-03-31 N-PORT

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments